IDEAYA Biosciences, Inc. $IDYA Shares Sold by Northern Trust Corp

Key Points

• Northern Trust Corp reduced its stake in IDEAYA Biosciences by 2.4%, now holding 753,529 shares valued at approximately $12.34 million.
• Several analysts have initiated coverage on IDEAYA Biosciences, with ratings ranging from "buy" to "market outperform," setting price targets between $25.00 and $45.00.
• IDEAYA reported a quarterly loss of ($0.88) per share, missing the estimate by ($0.03), but exceeded revenue expectations with $6.00 million compared to the anticipated $3.48 million.

Northern Trust Corp reduced its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 2.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 753,529 shares of the company's stock after selling 18,323 shares during the quarter. Northern Trust Corp owned about 0.86% of IDEAYA Biosciences worth $12,343,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Janus Henderson Group PLC grew its stake in IDEAYA Biosciences by 13.5% during the 4th quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock worth $150,606,000 after buying an additional 695,263 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of IDEAYA Biosciences by 0.3% during the first quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company's stock worth $83,417,000 after acquiring an additional 14,535 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its position in shares of IDEAYA Biosciences by 5.5% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,736,000 shares of the company's stock worth $70,315,000 after buying an additional 142,000 shares during the last quarter. Fiera Capital Corp increased its position in IDEAYA Biosciences by 2.1% during the first quarter. Fiera Capital Corp now owns 1,209,865 shares of the company's stock worth $19,818,000 after acquiring an additional 25,398 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of IDEAYA Biosciences by 5.9% in the 4th quarter. Bank of America Corp DE now owns 747,934 shares of the company's stock worth $19,222,000 after buying an additional 41,390 shares in the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Price Performance

IDYA stock traded down $0.03 on Wednesday, reaching $24.71. 1,455,338 shares of the company traded hands, compared to its average volume of 1,124,551. IDEAYA Biosciences, Inc. has a one year low of $13.45 and a one year high of $37.80. The firm has a fifty day simple moving average of $23.84 and a 200-day simple moving average of $20.70. The company has a market cap of $2.17 billion, a P/E ratio of -6.52 and a beta of 0.12.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The firm had revenue of $6.00 million during the quarter, compared to analysts' expectations of $3.48 million. During the same quarter in the prior year, the business posted ($0.68) EPS. IDEAYA Biosciences's revenue was up NaN% on a year-over-year basis. On average, sell-side analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Ratings Changes

IDYA has been the subject of a number of analyst reports. Citizens Jmp began coverage on IDEAYA Biosciences in a research note on Thursday, September 4th. They set a "mkt outperform" rating and a $41.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on IDEAYA Biosciences from $72.00 to $74.00 and gave the stock an "overweight" rating in a report on Wednesday, September 3rd. The Goldman Sachs Group upgraded IDEAYA Biosciences to a "hold" rating and set a $25.00 target price on the stock in a research report on Thursday, July 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a report on Tuesday. Finally, Citigroup reiterated a "buy" rating on shares of IDEAYA Biosciences in a report on Tuesday. Twelve investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $42.75.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.